Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Ryzumvi Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Single-patient-use vials (0.31mL)—30
Manufacturer
Generic Availability
NO
Mechanism of Action
Ryzumvi is a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist. Phentolamine reversibly binds to the alpha-1 adrenergic receptors on the iris dilator muscle, thereby reducing pupil diameter. Phentolamine directly antagonizes the mydriatic effect of an α-1 adrenergic agonist, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.
Ryzumvi Indications
Indications
Pharmacologically-induced mydriasis produced by adrenergic agonists (eg, phenylephrine) or parasympatholytic (eg, tropicamide) agents.
Ryzumvi Dosage and Administration
Adults and Children
<3yrs: not established. 3–11yrs: Instill 1 drop in each dilated eye after completing eye examination/procedure. ≥12yrs: Instill 1 or 2 drops in each dilated eye after completing eye examination/procedure; if 2 drops are used, separate drops by 5mins.
Ryzumvi Contraindications
Not Applicable
Ryzumvi Boxed Warnings
Not Applicable
Ryzumvi Warnings/Precautions
Warnings/Precautions
Active ocular inflammation (eg, iritis): not recommended. Contact lenses (remove; may reinsert lenses 10mins after administration). Pregnancy. Nursing mothers.
Ryzumvi Pharmacokinetics
Absorption
Peak concentration levels occurred between 15 minutes and 1 hour after dosing with the median value of 0.45 ng/mL.
Ryzumvi Interactions
Not Applicable
Ryzumvi Adverse Reactions
Adverse Reactions
Instillation site discomfort (pain, stinging, burning), conjunctival hyperemia, dysgeusia.
Ryzumvi Clinical Trials
See Literature
Ryzumvi Note
Not Applicable
Ryzumvi Patient Counseling
See Literature
Images
